The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to biopharma company Aridis Pharmaceuticals’ human monoclonal antibody Aerucin for the treatment of hospital acquired and ventilator associated pneumonia caused by Pseudomonas aeruginosa. Aridis completed enrollment and dosing in a Phase 1 clinical study of Aerucin. Results are expected in the fourth quarter of this year. “We are pleased to receive Fast Track designation for Aerucin as it provides an accelera...